NeuroVive Pharmaceutical AB Prix / Ventes
Quel est le Prix / Ventes de NeuroVive Pharmaceutical AB?
Le Prix / Ventes de NeuroVive Pharmaceutical AB est 1,207.19
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Miscellaneous secteur sur LSE par rapport à NeuroVive Pharmaceutical AB
Que fait NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Entreprises avec prix / ventes similaire à NeuroVive Pharmaceutical AB
- CytoDyn a Prix / Ventes de 1,174.39
- Cellular Biomedicine Inc a Prix / Ventes de 1,184.26
- Black Rock Mining a Prix / Ventes de 1,188.66
- Navidea Biopharmaceuticals Inc a Prix / Ventes de 1,194.84
- Kraig Biocraft Laboratories a Prix / Ventes de 1,199.03
- Buderim a Prix / Ventes de 1,206.67
- NeuroVive Pharmaceutical AB a Prix / Ventes de 1,207.19
- Strategic Elements Ltd a Prix / Ventes de 1,216.32
- Greenland Minerals a Prix / Ventes de 1,251.46
- Galantas Gold a Prix / Ventes de 1,271.42
- Kazia Therapeutics a Prix / Ventes de 1,276.66
- Tyranna Resources a Prix / Ventes de 1,282.36
- Leading Leasing Finance And Investment a Prix / Ventes de 1,283.53